Sangamo Therapeutics (SGMO) reported Q2 2025 results with revenue missing estimates at $18.31M but a narrower loss of $0.08/share. Shares fell 9% post-earnings despite positive Fabry disease trial progress.
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
